目的：通过光学相干断层扫描血流成像术(OCTA)观察玻璃体腔注射康柏西普治疗病理性近视脉络膜新生血管(pm-CNV)的疗效。

方法：回顾性分析23位患者26眼接受康柏西普治疗pm-CNV 1y的治疗效果。首诊中，所有患者通过荧光素眼底血管造影(FFA)和OCTA确诊为pm-CNV。所有患者均接受“1+PRN”的治疗方案。随访中，记录患者的最佳矫正视力(BCVA)，OCTA测量中心凹厚度(CFT)和CNV面积。

结果：1a后，平均BCVA(LogMAR)从基线视力0.66±0.51提升到0.39±0.38(t=3.528，P=0.004)。CFT在治疗前为(275.08±48.74)μm，治疗后1a，CFT为(205.15±43.74)μm(t=4.630，P=0.001)。CNV面积在治疗前的基线为(0.48±0.24)mm²，治疗后1a的面积为(0.15±0.11)mm²，具有明显的统计学差异(t=5.329，P=0.000)。有21眼行1次注射，4眼行2次注射，仅有1眼行3次注射。在治疗过程中，没有严重不良事件发生。

结论：应用“1+PRN”方案行玻璃体腔注射康柏西普可以提高pm-CNV患者视力，OCTA可以观察到CFT减轻和CNV面积的减小，但是长期的随访仍然要观察。

METHODS: The medical records of 26 consecutive eyes of 23 patients who received intravitreal injections of conbercept for pm-CNV with a follow-up of 1y were retrospectively reviewed. All the patients were diagnosed by fundus fluorescein angiography(FFA)and OCTA at the first visit. All approaches were performed as “1+PRN” treatment. Outcomes included best-corrected visual acuity(BCVA), central foveal thickness(CFT)and the mean CNV area by OCTA.

RESULTS: Mean BCVA improved from(0.66±0.51)at baseline to(0.39±0.38)at 1y(t=3.528, P=0.004). The CFT before treatment and after 1y after were(275.08±48.74)μm and(205.15±43.74)μm respectively(t=4.630, P=0.001). The mean pm-CNV areas before treatment and after 1y treatment were(0.48±0.24)mm² and(0.15±0.11)mm² respectively, with a significant difference among them(t=5.329, P=0.000). Twenty-one eyes had no needs after the first treatment. Four eyes received 2 injections and only one eye received 3 injections. No severe adverse events were noted relevant to the therapy.

CONCLUSION: Intravitreal conbercept can improve the vision and relieve CFT and CNV area for the treatment of pm-CNV with “1+PRN” by OCTA for 1y, however, long-term follow-up still need to be performed.